Neuraxis
NRXS

$2.95

2.32%

Market Cap: $20.2M

About: Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Employees: 19

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

33% more capital invested

Capital invested by funds: $233K [Q1] → $308K (+$75.7K) [Q2]

25% more funds holding

Funds holding: 8 [Q1] → 10 (+2) [Q2]

0.26% more ownership

Funds ownership: 1.41% [Q1] → 1.67% (+0.26%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for NRXS.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about NRXS published over the past 30 days

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

CARMEL, Ind., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Geisinger Health Plan, serving 600,000+ enrollees in central Pennsylvania. This medical policy will bring our national total coverage for PENFS to roughly 24 million insured lives, with more decisions from major payers still pending.

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending.

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript

NeurAxis, Inc. (NYSE:NRXS ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Conference Call Participants Mark Foster - Kirr Marbach & Co Operator Good day and thank you for standing by. Welcome to NeurAxis Reports Second Quarter 2024 Financial Results.

NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript

NeurAxis Reports Second Quarter 2024 Financial Results

Carmel, Ind., Aug. 09, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2024.

NeurAxis Reports Second Quarter 2024 Financial Results

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

CARMEL, Ind., June 07, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced a submission to the FDA for expansion of its IB-Stim label. The new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript

NeurAxis, Inc. (NYSE:NRXS ) Q1 2024 Earnings Conference Call May 22, 2024 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to NeurAxis Reports First Quarter 2024 Financial Results.

NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript

NeurAxis Reports First Quarter 2024 Financial Results

CARMEL, Ind., May 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2024 for the period ended March 31, 2024.

NeurAxis Reports First Quarter 2024 Financial Results

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

CARMEL, Ind., May 21, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

CARMEL, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2024, for the period ended March 31, 2024, on Wednesday, May 22, 2024, before market open. The Company has scheduled a conference call for the same day, Wednesday, May 22, 2024, at 9:00 am ET to review the results.

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

NeurAxis Announces New Medical Policy Coverage in North Dakota

CARMEL, Ind., April 23, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the publication of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), effective 05/06/2024, with a Blue Cross Blue Shield (BCBS) licensee in North Dakota. The BCBS licensee is the largest provider of health care coverage in North Dakota, insuring and/or administering claims for over 310,000 people, effective May 6, 2024.

NeurAxis Announces New Medical Policy Coverage in North Dakota

See News Rankings